NCT05593575已完成2 期
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 305
- 试验地点
- 45
- 主要终点
- Percentage change from baseline in UACR
研究概览
简要总结
To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are diagnosed with type 2 diabetes who have been treated with at least one hypoglycemic therapy within 12 months prior to screening, with basically stable blood glucose level during screening;
- •During screening period, 120 mmHg ≤ sitting SBP ≤ 160 mmHg and sitting DBP < 110 mmHg;
- •Laboratory results before randomization should be: 1) at least twice the result of UCAR should be 30 mg/g ≤ UACR < 3000mg/g at W-8, W-4, W-2, and W0; 2) EGFR ≥ 45mL/min/1.73 m2 at W-4 and W0; 3) AST and ALT ≤ 2 times the upper limit of normal (ULN), and total bilirubin ≤ 1.5 times ULN at W0; 4) hemoglobin ≥ 90 g/L at W0; 5) 3.5 mmol/L ≤Serum potassium ≤ 4.8 mmol/L at W-4 and W0;
- •Subjects who agree to take effective contraceptive measures with their spouses throughout the study period and for up to 12 weeks after the last dose;
- •Subjects who thoroughly learn about the nature, significance, possible benefits, possible inconvenience and potential risks of the trial, and understand the study procedures and voluntarily sign the informed consent form prior to their participation in the trial.
排除标准
- •Sitting SBP >140 mmHg and/or sitting DBP >90 mmHg at baseline (W0);
- •Color ultrasonography of renal artery indicated renal artery stenosis;
- •① Acute renal insufficiency② acute nephritic syndrome, polycystic kidney, kidney stone, nephrotic syndrome; ③there is evidence that proteinuria originates from primary and secondary renal diseases other than hypertensive renal damage; ④ gross hematuria in the past one year.
- •During the screening/run-in period, major modifications need to be made to the subject's corresponding treatment regimen due to poor control of other underlying diseases based on the investigator's judgement;
- •Subjects with fundus lesions in malignant hypertensive, such as retinal hemorrhage and papilledema;
- •Subjects who need to continuously take glucocorticoids, anti-tumor chemical or biological agents, and non-steroidal anti-inflammatory drugs during the study period;
- •Subjects with a history of acute myocardial infarction, coronary artery revascularization, Class IV heart failure, acute cerebral infarction, cerebral hemorrhage and transient ischemic attack within 3 months prior to randomization;
- •Subjects who have abnormal thyroid function tests with clinically significance;
- •Subjects with poor control of diabetes: HbA1c ≥ 9.0% at W0;
- •Subjects who have undergone major surgery within 3 months prior to screening or need to undergo major surgery during the trial;
- •Subjects whose medication adherence in the run-in period is < 80% or > 120%;
- •Subjects with a history of gastrointestinal surgery that may significantly change the absorption, distribution, metabolism and excretion of drugs;
- •Subjects who are known to be allergic to renin inhibitors, ARBs, ACEIs and their excipients, or those with hypersensitive constitution, or those who experience serious adverse reactions;
- •Women during pregnancy or lactating;
- •Subjects who need transplantation before randomization and during the trial;
- •Subjects with HIV infection, hepatitis B infection, hepatitis C infection, or other active infections;
- •Subjects who have a history of malignant tumor, and those who are suspected of malignant tumor;
- •Subjects with a past and current history of mental illness;
- •Subjects with a history of drug abuse or alcohol abuse within 2 years prior to screening;
- •Subjects who have participated in clinical trials of other drugs/devices as a subject within 3 months prior to screening;
- •Subjects with other diseases or conditions that the investigator considers not suitable for this trial.
研究组 & 干预措施
SPH3127-1
Experimental
1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
干预措施: SPH3127+SPH3127matching placebo+valsartan matching placebo (Drug)
SPH3127-2
Experimental
2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
干预措施: SPH3127+SPH3127matching placebo+valsartan matching placebo (Drug)
SPH3127-3
Experimental
4 tablet of SPH3127 (50 mg) ，1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
干预措施: SPH3127+valsartan matching placebo (Drug)
SPH3127-4
Experimental
4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan , orally, once daily for 12 consecutive weeks
干预措施: SPH3127 matching placebo+valsartan (Drug)
结局指标
主要结局
Percentage change from baseline in UACR
时间窗: at the end of Week 12 of treatment
Percentage change from baseline in log-transformed UACR at the end of Week 12 of treatment
次要结局
- Percentage change from baseline in UACR(at the end of Weeks 2, 4 and 8 of treatment)
- Percentage change from baseline in UPCR(at the end of Weeks 2, 4, 8 and 12 of treatment)
- The change trend of eGFR(from baseline to the end of Weeks 2, 4, 8 and 12 of treatment)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative ColitisMild to Moderate Ulcerative ColitisNCT05770609Shanghai Pharmaceuticals Holding Co., Ltd53
已完成
2 期
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on HemodialysisEnd Stage Renal DiseaseChronic Kidney Disease Stage 5ESRDNCT01764854Ardelyx88
已完成
2 期
A Study in CKD Patients With Type 2 Diabetes Mellitus and AlbuminuriaType 2 Diabetes MellitusChronic Kidney DiseaseNCT01847092Ardelyx154
终止
2 期
Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal ImpairmentKidney FailureHeart FailureNCT00881439University Medical Center Groningen41
已完成
1 期
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential HypertensionHypertensionNCT00424541Novartis34